Asset Details
Do you wish to reserve the book?
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
Do you wish to request the book?
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The State of Synthetic Cannabinoid Medications for the Treatment of Pain
2024
Overview
Synthetic cannabinoids are compounds made in the laboratory to structurally and functionally mimic phytocannabinoids from the
Cannabis sativa
L
.
plant, including delta-9-tetrahydrocannabinol (THC). Synthetic cannabinoids (SCs) can signal via the classical endogenous cannabinoid system (ECS) and the greater endocannabidiome network, highlighting their signalling complexity and far-reaching effects. Dronabinol and nabilone, which mimic THC signalling, have been approved by the Food and Drug Administration (FDA) for treating nausea associated with cancer chemotherapy and/or acquired immunodeficiency syndrome (AIDS). However, there is ongoing interest in these two drugs as potential analgesics for a variety of other clinical conditions, including neuropathic pain, spasticity-related pain, and nociplastic pain syndromes including fibromyalgia, osteoarthritis, and postoperative pain, among others. In this review, we highlight the signalling mechanisms of FDA-approved synthetic cannabinoids, discuss key clinical trials that investigate their analgesic potential, and illustrate challenges faced when bringing synthetic cannabinoids to the clinic.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
Acquired immune deficiency syndrome
/ AIDS
/ Analgesics - therapeutic use
/ Animals
/ Cannabinoids - adverse effects
/ Cannabinoids - chemical synthesis
/ Cannabinoids - therapeutic use
/ Cannabis
/ Dronabinol - therapeutic use
/ Humans
/ Ligands
/ Medicine
/ Nausea
/ Saliva
/ Synthetic Drugs - pharmacology
/ Synthetic Drugs - therapeutic use
/ THC
